GO:0000710

BP

meiotic mismatch repair

A system for the identification and correction of base-base mismatches, small insertion-deletion loops, and regions of heterology that are present in duplex DNA formed with strands from two recombining molecules. Correction of the mismatch can result in non-Mendelian segregation of alleles following meiosis.

ERCC1, MSH3, MSH2, MSH6

GO:0000712

BP

resolution of meiotic recombination intermediates

The cleavage and rejoining of intermediates, such as Holliday junctions, formed during meiotic recombination to produce two intact molecules in which genetic material has been exchanged.

EME2, STRA13, TOP2A, MLH1, FANCM, APITD1, ERCC4, EME1

GO:0000715

BP

nucleotide-excision repair, DNA damage recognition

The identification of lesions in DNA, such as pyrimidine-dimers, intrastrand cross-links, and bulky adducts. The wide range of substrate specificity suggests the repair complex recognizes distortions in the DNA helix.

PARP1, UBC, XPA, RAD23B, RBX1, RPS27A, UBA52, XPC, CUL4A, CUL4B, COPS6, COPS8, COPS7B

GO:0000717

BP

nucleotide-excision repair, DNA duplex unwinding

The unwinding, or local denaturation, of the DNA duplex to create a bubble around the site of the DNA damage.

PARP1, UBC, ERCC2, XPA, GTF2H1, RAD23B, RBX1, RPS27A, UBA52, XPC, CUL4A, CUL4B, GTF2H2, CHD1L, GTF2H4

GO:0000720

BP

pyrimidine dimer repair by nucleotide-excision repair

The repair of UV-induced T-T, C-T, and C-C dimers by the recognition and removal of the damaged DNA strand from the DNA helix as an oligonucleotide. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase.

ERCC1

GO:0000722

BP

telomere maintenance via recombination

Any recombinational process that contributes to the maintenance of proper telomeric length.

RAD51C, POLA1, PCNA, LIG1, POLD1, RPA3, RFC4, RFC2, FEN1, RFC5, RFC3, PRIM1, PRIM2, DNA2, BRCA2, POLE2, RAD51, POLE, POLA2, POLD3, SMC5, RAD50, SMC6, TEP1, POLD4

GO:0000723

BP

telomere maintenance

Any process that contributes to the maintenance of proper telomeric length and structure by affecting and monitoring the activity of telomeric proteins, the length of telomeric DNA and the replication and repair of the DNA. These processes includes those that shorten, lengthen, replicate and repair the telomeric DNA sequences.

NBN, RAD51D, PCNA, XRCC5, SP100, POLD1, DNA2, TERF1, POLD3, PTGES3, RAD50, ERCC4, ACD, SMG1, PIF1, OBFC1, POLD4

GO:0000724

BP

double-strand break repair via homologous recombination

The error-free repair of a double-strand break in DNA in which the broken DNA molecule is repaired using homologous sequences. A strand in the broken DNA searches for a homologous region in an intact chromosome to serve as the template for DNA synthesis. The restoration of two intact DNA molecules results in the exchange, reciprocal or nonreciprocal, of genetic material between the intact DNA molecule and the broken DNA molecule.

AP5Z1, RAD51C, NBN, POLQ, RAD51D, FSBP, PARP1, H2AFX, SFPQ, YY1, RPA3, BRCA1, FEN1, RECQL, MRE11A, BRCA2, BLM, SHFM1, RAD51, SPIDR, SWI5, SMC5, FBXO18, WDR48, HELQ, RAD54L, RAD50, ERCC4, NABP1, RAD51AP1, TONSL, SMC6, NABP2, NUCKS1, MORF4L1, MCM8, FAN1, RAD54B

GO:0000725

BP

recombinational repair

A DNA repair process that involves the exchange, reciprocal or nonreciprocal, of genetic material between the broken DNA molecule and a homologous region of DNA.

RHNO1

GO:0000727

BP

double-strand break repair via break-induced replication

The error-free repair of a double-strand break in DNA in which the centromere-proximal end of a broken chromosome searches for a homologous region in an intact chromosome. DNA synthesis initiates from the 3' end of the invading DNA strand, using the intact chromosome as the template, and progresses to the end of the chromosome.

CDC7, GINS4, GINS2

GO:0000729

BP

DNA double-strand break processing

The 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang.

NBN, BRCA1, MRE11A, DNA2, BLM, UBE2V2, RAD50, BARD1, SMARCAD1

GO:0000730

BP

DNA recombinase assembly

The aggregation, arrangement and bonding together of strand exchange proteins (recombinases) into higher order oligomers on single-stranded DNA.

RAD51C, RAD51, SWI5

GO:0000731

BP

DNA synthesis involved in DNA repair

Synthesis of DNA that proceeds from the broken 3' single-strand DNA end and uses the homologous intact duplex as the template.

RAD51C, NBN, RAD51D, POLD1, BRCA1, RFC3, MRE11A, DNA2, BRCA2, BLM, RAD51, POLE, POLD3, RAD50, RAD51AP1, BARD1, POLD4, EXO1, POLH

GO:0000732

BP

strand displacement

The rejection of the broken 3' single-strand DNA molecule that formed heteroduplex DNA with its complement in an intact duplex DNA. The Watson-Crick base pairing in the original duplex is restored. The rejected 3' single-strand DNA molecule reanneals with its original complement to reform two intact duplex molecules.

RAD51C, NBN, RAD51D, BRCA1, MRE11A, DNA2, BRCA2, BLM, RAD51, RAD50, RAD51AP1, BARD1, EXO1

GO:0000733

BP

DNA strand renaturation

The identification and annealing of complementary base pairs in single-strand DNA.

RECQL4, ANXA1, TP53, SMARCA1, RECQL, BLM, RAD54L

GO:0000737

BP

DNA catabolic process, endonucleolytic

The chemical reactions and pathways resulting in the breakdown of DNA, involving the hydrolysis of internal 3',5'-phosphodiester bonds in one or two strands of deoxyribonucleotides.

FBXO18

GO:0000738

BP

DNA catabolic process, exonucleolytic

The chemical reactions and pathways resulting in the breakdown of DNA, involving the hydrolysis of terminal 3',5'-phosphodiester bonds in one or two strands of deoxyribonucleotides.

ISG20

GO:0000819

BP

sister chromatid segregation

The cell cycle process in which sister chromatids are organized and then physically separated and apportioned to two or more sets.

LATS1, TOP2A

GO:0000821

BP

regulation of arginine metabolic process

Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving arginine, 2-amino-5-(carbamimidamido)pentanoic acid.

SLC7A7

GO:0000902

BP

cell morphogenesis

The developmental process in which the size or shape of a cell is generated and organized.

GREM1, RP2, CLU, VDR, IL7R, SOX6, LIPA, PSMB10, BCL6, YAP1, CSNK1A1, WNT3, TGFB2, ADAM8, NRG1, STK4, SART3, MAPK14, PTPRO, FRY, TENM4, PDPN, SHROOM3, ARHGEF2, STRADB, ECT2, NOX4, TBCCD1, TENM3, KLF2

GO:0000904

BP

cell morphogenesis involved in differentiation

The change in form (cell shape and size) that occurs when relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history.

DKK1, LAMC3

GO:0000910

BP

cytokinesis

The division of the cytoplasm and the plasma membrane of a cell and its partitioning into two daughter cells.

DAPK3, PRC1, DIAPH2, ROCK2, RAB11FIP3, KIF20A, RALA, RALB, MYH9, BRCA2, PLK1, IST1, RAB11A, RHOB, KIF23, SEPT6, ESPL1, SEPT7, MAP9, TTC19, PIK3C3, NEK7, AHCTF1, NOX5, ECT2, NEK6, KLHL9, KLHL13

GO:0000915

BP

actomyosin contractile ring assembly

The process of assembly of a ring composed of actin, myosin, and associated proteins that will function in cytokinesis.

KIF23, RACGAP1

GO:0000920

BP

cell separation after cytokinesis

The process of physically separating progeny cells after cytokinesis; this may involve enzymatic digestion of septum or cell wall components.

CHMP2A, VPS4B, KIF20A, CEP55, PDCD6IP, MITD1, CHMP4B

GO:0000921

BP

septin ring assembly

The aggregation, arrangement and bonding together of septins and associated proteins to form an organized structure resembling a ring at the cell cortex.

ANLN

GO:0000956

BP

nuclear-transcribed mRNA catabolic process

The chemical reactions and pathways resulting in the breakdown of nuclear-transcribed mRNAs in eukaryotic cells.

EXOSC9, XRN1, EXOSC4, MRTO4, THRAP3, LSM5, LSM4

GO:0000957

BP

mitochondrial RNA catabolic process

The chemical reactions and pathways resulting in the breakdown of RNA transcribed from the mitochondrial genome and occurring in the mitochondrion.

PNPT1

GO:0000958

BP

mitochondrial mRNA catabolic process

The chemical reactions and pathways resulting in the breakdown of mRNA transcribed from the mitochondrial genome and occurring in the mitochondrion.

SUPV3L1, PNPT1

GO:0000961

BP

negative regulation of mitochondrial RNA catabolic process

Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving catabolism in the mitochondrion of RNA transcribed from the mitochondrial genome.

LRPPRC, SLIRP

GO:0000962

BP

positive regulation of mitochondrial RNA catabolic process

Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving catabolism in the mitochondrion of RNA transcribed from the mitochondrial genome.

SUPV3L1, PNPT1

GO:0000964

BP

mitochondrial RNA 5'-end processing

Any process involved in forming the mature 5' end of an RNA molecule transcribed from a mitochondrial genome; occurs in the mitochondrion.

PNPT1

GO:0000965

BP

mitochondrial RNA 3'-end processing

Any process involved in forming the mature 3' end of an RNA molecule transcribed from a mitochondrial genome; occurs in the mitochondrion.

SUPV3L1, PNPT1

GO:0000972

BP

transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery

The chromosome organization process in which the DNA sequence containing a gene transcribed by RNA polymerase II is maintained in a specific location at the nuclear periphery. In S. cerevisiae, this process involves cis-acting DNA sequences such as the TATA box and upstream activating sequence (UAS) elements, trans-acting transcriptional activators, and also the 3'-UTR of the transcript.

NUP155, RAE1

GO:0000973

BP

posttranscriptional tethering of RNA polymerase II gene DNA at nuclear periphery

The chromosome organization process in which the DNA sequence containing a gene transcribed by RNA polymerase II is maintained in a specific location at the nuclear periphery even after transcription has been repressed.

NUP107

GO:0001080

BP

nitrogen catabolite activation of transcription from RNA polymerase II promoter

A transcription regulation process in which the presence of one nitrogen source leads to an increase in the frequency, rate, or extent of transcription, from an RNA polymerase II promoter, of specific genes involved in the metabolism of other nitrogen sources.

NR1H4

GO:0001100

BP

negative regulation of exit from mitosis

Any process involved in the inhibition of progression from anaphase/telophase (high mitotic CDK activity) to G1 (low mitotic CDK activity).

RGCC

GO:0001172

BP

transcription, RNA-templated

The cellular synthesis of RNA on a template of RNA.

POLR2A

GO:0001189

BP

RNA polymerase I transcriptional preinitiation complex assembly at the promoter for the nuclear large rRNA transcript

The aggregation, arrangement and bonding together of proteins on CORE promoter element DNA of the nuclear large ribosomal RNA (rRNA) transcript to form a transcriptional preinitiation complex (PIC), the formation of which is a prerequisite for transcription from the large rRNA promoter, resulting in the subsequent synthesis of the large rRNA transcript.

TAF1B, POLR1E

GO:0001193

BP

maintenance of transcriptional fidelity during DNA-templated transcription elongation from RNA polymerase II promoter

Suppression of the occurrence of transcriptional errors, such as substitutions and/or insertions of nucleotides that do not correctly match the template base, during the process of transcription elongation from an RNA polymerase II promoter.

POLR2I

GO:0001300

BP

chronological cell aging

The process associated with progression of the cell from its inception to the end of its lifespan that occurs when the cell is in a non-dividing, or quiescent, state.

SERPINE1

GO:0001302

BP

replicative cell aging

The process associated with progression of the cell from its inception to the end of its lifespan that occurs as the cell continues cycles of growth and division.

ERCC1, ROMO1

GO:0001315

BP

age-dependent response to reactive oxygen species

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of reactive oxygen species, where the change varies according to the age of the cell or organism.

SOD2

GO:0001501

BP

skeletal system development

The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton).

SH3PXD2B, TNFRSF11B, NCAN, SHOX2, USP1, PAPSS2, GDF11, PTH, IGF2, COL1A1, COL3A1, AHSG, BGLAP, IGF1, INHA, ALPL, COL5A2, COL1A2, TRAPPC2, GLI2, HAPLN1, FGFR1, VDR, PTHLH, BMP2, BMP3, BMP1, VCAN, COL11A2, MMP9, ETS2, NPR3, BMP6, IGFBP4, GNA11, HOXA10, BMP8B, FBN1, GJA5, TGFBR1, SOX9, COMP, CDKN1C, GNAQ, CDH11, DLX5, HDAC4, EVC, TGFB2, RPL38, COL10A1, PRDX1, SOX4, AES, FOXC1, SPP2, KLF10, TCOF1, POSTN, EBP, TEAD4, EXT1, AEBP1, UFD1L, ACD, BCAN, COL12A1, ANKH, DSPP, CHD7, TRPS1, SUFU, HSPB11

GO:0001502

BP

cartilage condensation

The condensation of mesenchymal cells that have been committed to differentiate into chondrocytes.

MYCN, MGP, THRA, COL11A1, BMP1, CTGF, SOX9, TGFB2, PKD1, MAPK14

GO:0001503

BP

ossification

The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance.

TNFSF11, EGFR, IGF2, AHSG, CLEC3B, COL5A2, MGP, SPARC, BCL2, THRA, COL11A1, IFITM1, BMP1, MMP9, ALOX15, NPR2, CTGF, BMP8B, SOX9, SLC26A2, STC1, CDH11, RPL38, GPLD1, RUNX1, SP3, FOXC1, GPM6B, RUNX3, RUNX2, TWIST1, EXT1, BMP8A, PPARGC1B, EXT2, KAZALD1, SOST, DHX36, PDLIM7, DSPP, MINPP1, PAM16, TNFRSF11A

GO:0001504

BP

neurotransmitter uptake

The directed movement of neurotransmitters into neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.

SLC1A3, ATP1A2, SNAP25, SV2A, SV2B, SLC38A1

GO:0001507

BP

acetylcholine catabolic process in synaptic cleft

The chemical reactions and pathways resulting in the breakdown of acetylcholine that occurs in the synaptic cleft during synaptic transmission.

COLQ

GO:0001508

BP

action potential

A process in which membrane potential cycles through a depolarizing spike, triggered in response to depolarization above some threshold, followed by repolarization. This cycle is driven by the flow of ions through various voltage gated channels with different thresholds and ion specificities.

GNA11, SRI, GNAQ, AKAP6, CLN3

GO:0001510

BP

RNA methylation

Posttranscriptional addition of a methyl group to either a nucleotide or 2'-O ribose in a polyribonucleotide. Usually uses S-adenosylmethionine as a cofactor.

BCDIN3D

GO:0001514

BP

selenocysteine incorporation

The incorporation of selenocysteine into a peptide; uses a special tRNA that recognizes the UGA codon as selenocysteine, rather than as a termination codon. Selenocysteine is synthesized from serine before its incorporation; it is not a posttranslational modification of peptidyl-cysteine.

SELT, DIO2, SECISBP2L, SECISBP2, SEPSECS, TRNAU1AP

GO:0001516

BP

prostaglandin biosynthetic process

The chemical reactions and pathways resulting in the formation of prostaglandins, any of a group of biologically active metabolites which contain a cyclopentane ring.

PTGES, CD74, EDN1, MIF, EDN2, PTGS1, PTGS2, PTGDS, PTGES3, PTGIS, PNPLA8

GO:0001519

BP

peptide amidation

The posttranslational conversion of C-terminal glycine-extended peptides to C-terminal alpha-amidated peptides. Occurs to over half of all peptide hormones to give bioactive peptides. This is a two step process catalyzed by a peptidyl-glycine alpha-hydroxylating monooxygenase and a peptidyl-alpha-hydroxyglycine alpha-amidating lyase. In some organisms, this process is catalyzed by two separate enzymes, whereas in higher organisms, one polypeptide catalyzes both reactions.

PAM, PGLYRP2

GO:0001522

BP

pseudouridine synthesis

The intramolecular conversion of uridine to pseudouridine within an RNA molecule. This posttranscriptional base modification occurs in tRNA, rRNA, and snRNAs.

NAF1, PUS7, NOP10

GO:0001523

BP

retinoid metabolic process

The chemical reactions and pathways involving retinoids, any member of a class of isoprenoids that contain or are derived from four prenyl groups linked head-to-tail. Retinoids include retinol and retinal and structurally similar natural derivatives or synthetic compounds, but need not have vitamin A activity.

SDC3, GPC4, DHRS3, APOA1, APOE, APOA2, APOC3, RBP4, TTR, OPN1SW, APOB, LPL, RBP1, SDC1, SDC4, SDC2, GPC1, ADH7, AKR1C3, HSPG2, LRP2, AKR1C1, NAPEPLD, CYP4V2, RDH10, GPC2, RDH11, RARRES2, GPC6

GO:0001525

BP

angiogenesis

Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.

MEIS1, KRIT1, NRP1, EREG, ANGPT2, HOXA3, TBX1, HS6ST1, NRP2, SRPX2, RAMP1, PDCD6, FGF18, TSPAN12, FN1, ANG, PDGFA, APOD, SERPINE1, JUN, GPI, ITGAV, ANXA2, MMP2, COL4A2, ITGA5, HMOX1, CXCL8, FGFR1, CCL2, SCG2, VEGFA, PRKCA, TAL1, XBP1, TYMP, EFNA1, S1PR1, SAT1, FGFR2, PTPRB, COL8A2, CTGF, EPHB2, NOS3, S100A7, FGF9, PTGS2, RORA, MYH9, TIE1, GJA5, COL15A1, COL18A1, ID1, LEP, ELK3, PIK3CA, MCAM, SYK, LEPR, PIK3CG, PGF, VEGFB, VEGFC, MMP14, PLCD1, PRKX, EPHB4, EPHB1, PTEN, TGFB2, RHOB, ADAM8, SRPK2, JAG1, HSPG2, TEK, CAV1, TNFAIP2, PTK2, MFGE8, PDE3B, IL18, VEZF1, PRKD1, SHB, TGFBI, MAPK14, HIF1A, CYP1B1, CSPG4, ARHGAP22, TMPRSS6, UNC5B, ARHGAP24, AGGF1, NDNF, STAB2, NRCAM, MYDGF, APOLD1, NOX5, MMP19, EPAS1, CIB1, PDCD10, HTATIP2, JAM3, NAA15, PRKD2, PDCL3, SEMA4A, FZD8, SOX17, TNFRSF12A, ESM1, DLL4, ERAP1, VAV3, THSD7A, HIF3A, PLXND1, HEY1, ADGRG1, WASF2

GO:0001541

BP

ovarian follicle development

The process whose specific outcome is the progression of the ovarian follicle over time, from its formation to the mature structure.

FANCG, BMP15, ANG, INHA, ICAM1, INHBA, INHBB, BCL2, KIT, VEGFA, CEBPB, KITLG, CTNNA1, MMP14, FOXL2, BAX, FOXC1, EIF2B5, SMAD4, MMP19, EIF2B4, KMT2B, PCYT1B

GO:0001542

BP

ovulation from ovarian follicle

The process leading to the rupture of the follicle, releasing the centrally located oocyte into the oviduct. An example of this is found in Mus musculus.

FOXO3, NOS3, LEP, MMP19, ADAMTS1

GO:0001543

BP

ovarian follicle rupture

Disruption of theca cell layer releasing follicular fluid and/or the oocyte.

NRIP1

GO:0001544

BP

initiation of primordial ovarian follicle growth

Increase in size of primordial follicles including proliferation and shape changes of granulosa and/or theca cells until oocyte is surrounded by one layer of cuboidal shaped granulosa cells (primary follicle).

FOXO3

GO:0001545

BP

primary ovarian follicle growth

Increase in size of primary follicles including oocyte growth and granulosa and/or theca cell proliferation until more than one layer of granulosa cells is present (preantral follicle).

FSHR

GO:0001546

BP

preantral ovarian follicle growth

Increase in size of follicles surrounded by two or more layers of granulosa cells up to the onset of antrum formation.

AMH

GO:0001547

BP

antral ovarian follicle growth

Increase in size of antral follicles due to cell proliferation and/or growth of the antral cavity.

FOXO3, ESR1

GO:0001550

BP

ovarian cumulus expansion

Increase in size of the cumulus surrounding the oocyte including change in morphology due to proliferation and dispersion of cumulus cells.

EREG

GO:0001553

BP

luteinization

The set of processes resulting in differentiation of theca and granulosa cells into luteal cells and in the formation of a corpus luteum after ovulation.

PDGFRA, STAT5B

GO:0001554

BP

luteolysis

The lysis or structural demise of the corpus luteum. During normal luteolysis, two closely related events occur. First, there is loss of the capacity to synthesize and secrete progesterone (functional luteolysis) followed by loss of the cells that comprise the corpus luteum (structural luteolysis). Preventing luteolysis is crucial to maintain pregnancy.

MMP19

GO:0001555

BP

oocyte growth

The developmental growth process in which an oocyte irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.

GDF9, FOXL2

GO:0001556

BP

oocyte maturation

A developmental process, independent of morphogenetic (shape) change, that is required for an oocyte to attain its fully functional state. Oocyte maturation commences after reinitiation of meiosis commonly starting with germinal vesicle breakdown, and continues up to the second meiotic arrest prior to fertilization.

EREG, FOXO3, ANG, CCNB1, CDC25B, BRCA2, PDE3A, RPS6KA2, TRIP13, PABPC1L, FBXO5

GO:0001558

BP

regulation of cell growth

Any process that modulates the frequency, rate, extent or direction of cell growth.

EBAG9, CYR61, SOCS2, WISP2, URI1, CLSTN1, WISP1, AGT, RB1, IGFBP3, IGFBP2, CDK11B, IGFBP4, IGFBP6, IGFBP5, CTGF, AGTR1, HTRA3, PRKCQ, DDR1, CAMK2D, KIF14, STK11, IGFBP7, TMEM97, RASGRP2, NET1, NANOS1, BAP1, HTRA1, SGK3, KAZALD1, ITCH, BLZF1, WFDC1, CD320, ESM1, IL17RB, CRIM1, TAOK2, CDK11A, EPB41L3

GO:0001561

BP

fatty acid alpha-oxidation

A metabolic pathway by which 3-methyl branched fatty acids are degraded. These compounds are not degraded by the normal peroxisomal beta-oxidation pathway, because the 3-methyl blocks the dehydrogenation of the hydroxyl group by hydroxyacyl-CoA dehydrogenase. The 3-methyl branched fatty acid is converted in several steps to pristenic acid, which can then feed into the beta-oxidative pathway.

SLC27A2, SLC25A17, ALDH3A2

GO:0001562

BP

response to protozoan

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a protozoan.

VTCN1

GO:0001568

BP

blood vessel development

The process whose specific outcome is the progression of a blood vessel over time, from its formation to the mature structure. The blood vessel is the vasculature carrying blood.

PLPP3, TBX1, ALDH1A2, COL1A1, COL1A2, COL5A1, AHR, TGFBR2, CRKL, PSEN1, MDM2, MEF2C, FOXO1, RAPGEF1, MIB1, TCF7L2, SPHK1, DHCR7

GO:0001569

BP

patterning of blood vessels

The process that regulates the coordinated growth and sprouting of blood vessels giving rise to the organized vascular system.

NRP1, SEMA3E, EDN1, VEGFA, EDNRA, CTNNB1, TGFBR2, ACVR1, STK4, NFATC4, RBM15, PITX2, DLL4, PLXND1

GO:0001570

BP

vasculogenesis

The differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes.

TGFB1, VEGFA, JUNB, TNNI3, WT1, RASA1, ADM, TIE1, GJC1, TGFBR2, YAP1, HHEX, CAV1, PTK2, ZFP36L1, MYO1E, CUL7, TEAD2, NTRK2, AMOT, AGGF1, HDAC7, ZFPM2, HAS2, GLMN, QKI, PITX2, CITED1, CCM2, SOX17, HEG1, ZMIZ1, FZD4

GO:0001573

BP

ganglioside metabolic process

The chemical reactions and pathways involving ceramide oligosaccharides carrying in addition to other sugar residues, one or more sialic acid residues.

ITGB8, CLN6

GO:0001574

BP

ganglioside biosynthetic process

The chemical reactions and pathways resulting in the formation of ceramide oligosaccharides carrying in addition to other sugar residues, one or more sialic acid residues.

ST8SIA6, ST3GAL1, ST3GAL3, ST3GAL4, ST3GAL2, ST8SIA4, ST6GALNAC5, ST6GALNAC4, ST6GALNAC2, ST3GAL6

GO:0001575

BP

globoside metabolic process

The chemical reactions and pathways involving globosides, globotetraosylceramides, ceramides containing a core structure of GalNAc-beta-(1->3)-Gal-alpha-(1->4)-Glc(I). Globosides are the major neutral glycosphingolipid in normal kidneys and erythrocytes.

CLN3

GO:0001578

BP

microtubule bundle formation

A process that results in a parallel arrangement of microtubules.

PRC1, ZNF207, TPPP, KIF20A, MAP2, CLIP1, MAP1B, PLK1, PSRC1, NAV1, MARK4, CHP1, SPAST

GO:0001579

BP

medium-chain fatty acid transport

The directed movement of medium-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A medium-chain fatty acid is a fatty acid with a chain length of between C6 and C12.

SLC27A4, SLC27A1

GO:0001580

BP

detection of chemical stimulus involved in sensory perception of bitter taste

The series of events required for a bitter taste stimulus to be received and converted to a molecular signal.

CST2, AZGP1

GO:0001649

BP

osteoblast differentiation

The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone.

CYR61, SNAI2, SYNCRIP, SHOX2, SEMA7A, RSL1D1, PENK, COL1A1, BGLAP, ALPL, HNRNPC, CCL3, SPP1, COL6A1, BMP2, BMP4, BMP3, VCAN, JUNB, GJA1, IGFBP3, BMP6, IGFBP5, TNC, FGF9, AKT1, PHB, PSMC2, RBMX, FASN, HSD17B4, HIRA, DLX5, SOX8, HSPE1, RRAS2, RPS11, TPM4, H3F3A, HNRNPU, MEF2C, RUNX2, CBFB, MEF2D, GPNMB, TWIST1, ALYREF, TP53INP2, SFRP1, CCDC47, CREB3L1, MYBBP1A, LGR4, RRBP1, ITGA11, ASF1A

GO:0001654

BP

eye development

The process whose specific outcome is the progression of the eye over time, from its formation to the mature structure. The eye is the organ of sight.

SH3PXD2B, CST3, RBP4, ATF6, BMP6, FGF9, TGFB2, FOXC1, BLOC1S3, BBS7, ADAMTS18, HIPK2

GO:0001655

BP

urogenital system development

The process whose specific outcome is the progression of the urogenital system over time, from its formation to the mature structure.

AMH, SRD5A1, EPHB2, PAX8, OSR1, ACD

GO:0001656

BP

metanephros development

The process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. In mammals, the metanephros is the excretory organ of the fetus, which develops into the mature kidney and is formed from the rear portion of the nephrogenic cord. The metanephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.

SPRY1, GDF11, CTSH, GLI3, BCL2, FBN1, IRX3, ID2, ID3, NIPBL, RDH10, APH1A, CITED1, ROBO2

GO:0001657

BP

ureteric bud development

The process whose specific outcome is the progression of the ureteric bud over time, from its formation to the mature structure.

SMAD7, SMAD9, SMAD6, SPRY1, TCF21, SLIT2, GDF11, TGFB1, FGFR1, BMP4, EPCAM, SDC1, WT1, FGFR2, SDC4, SIM1, SMAD3, FOXC1, SMAD2, SMAD1, SFRP1, BMPER, OSR1, SMAD5, ROBO2

GO:0001658

BP

branching involved in ureteric bud morphogenesis

The process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.

TCF21, GREM1, MYC, FGF2, GLI3, BCL2, BMP2, BMP4, WT1, CTNNB1, PBX1, SOX9, PGF, PAX8, DLG1, ILK, SMAD4, PKD2, PTCH1, CITED1, WNT6

GO:0001659

BP

temperature homeostasis

A homeostatic process in which an organism modulates its internal body temperature.

GPX1, ADRB1, ADRB3, DRD2, EDN2, ADORA1, STAT3, ACADVL, FOXO1, ARRDC3, FTO, PPARGC1A

GO:0001660

BP

fever generation

The heat generation process that results in a rise in body temperature above the normal, often as a response to infection.

IL1A, IL1B, TRPV1

GO:0001661

BP

conditioned taste aversion

A conditioned aversion to a specific chemical compound as a result of that compound being coupled with a noxious stimulus.

FOS

GO:0001662

BP

behavioral fear response

An acute behavioral change resulting from a perceived external threat.

BRINP1, PENK, CCK, EIF4E, BCL2, MDK, DPP4, HTR2C, GABRA5, NPY2R, USP46, MAPK8IP2, LYPD1, FBXL20, ALS2

GO:0001666

BP

response to hypoxia

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.

PDLIM1, PLOD2, ANGPT2, CLDN3, ACTN4, TLR2, NOL3, LDHA, PLAU, PLAT, ADA, CST3, TGFB1, PENK, CRYAB, ANG, RAF1, CYP1A1, ATP1B1, PRKCB, TH, THBS1, MMP2, SOD3, HSPD1, BMP2, CCL2, ALAD, DRD2, HSP90B1, ETS1, VEGFA, CREB1, ITGA2, ERCC2, EGR1, PAM, VCAM1, TRH, AHCY, CD24, EDNRA, MT3, DPP4, ARNT, CASP1, ADORA1, ADSL, ADM, CHRNA7, TGFBR2, LEP, MTHFR, NR4A2, CDKN1B, CXCL12, PGF, VEGFB, VEGFC, PSEN2, MMP14, UCP2, UCP3, CXCR4, TGFB2, ADAM17, HSD11B2, ABAT, SMAD3, TEK, PLOD1, CAV1, TGFBR3, PPARA, EP300, KCNMA1, BNIP3, SMAD4, CAMK2D, ITPR2, ITPR1, POSTN, ADIPOQ, HIF1A, ALKBH5, AGTRAP, CYGB, RYR2, CREBBP, AJUBA, APOLD1, TXN2, EPAS1, CITED2, EGLN3, NOX4, DDIT4, DNMT3B, LIMD1, LOXL2

GO:0001667

BP

ameboidal-type cell migration

Cell migration that is accomplished by extension and retraction of a pseudopodium.

CENPV, WASF2

GO:0001672

BP

regulation of chromatin assembly or disassembly

Any process that modulates the frequency, rate or extent of chromatin assembly or disassembly.

TLK1

GO:0001675

BP

acrosome assembly

The formation of the acrosome from the spermatid Golgi.

RFX2, AGFG1, TMF1, CASC5

GO:0001676

BP

long-chain fatty acid metabolic process

The chemical reactions and pathways involving long-chain fatty acids, A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.

SLC27A2, ACSL4, PAM, ACSL1, CPT1A, SLC27A4, SLC27A1, ACOT4, ACSL6, SLC27A6

GO:0001678

BP

cellular glucose homeostasis

A cellular homeostatic process involved in the maintenance of an internal steady state of glucose within a cell or between a cell and its external environment.

HK1, PIK3R1, FOXO1, CARTPT, HKDC1, NUCKS1, PPARGC1A

GO:0001680

BP

tRNA 3'-terminal CCA addition

Post-transcriptional addition of the terminal 3' CCA sequence to a tRNA which does not encode this sequence within the primary transcript. CCA addition proceeds by the sequential addition of CTP, CTP, and then ATP to the 3' end of the tRNA, yielding a diphosphate with each nucleotide addition.

TRNT1

GO:0001682

BP

tRNA 5'-leader removal

Generation of the mature 5'-end of the tRNA, usually via an endonucleolytic cleavage by RNase P.

KIAA0391, POP7, RPP40, POP4, RPP30, POP5, RPP25

GO:0001692

BP

histamine metabolic process

The chemical reactions and pathways involving histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.

TRH

GO:0001695

BP

histamine catabolic process

The chemical reactions and pathways resulting in the breakdown of histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.

HNMT

GO:0001696

BP

gastric acid secretion

The regulated release of gastric acid (hydrochloric acid) by parietal or oxyntic cells during digestion.

CCKBR, NMU, GHRL